. Neural mass model (NMM) has been widely used to investigate the neurophysiological mechanisms of anesthetic drugs induced general anesthesia (GA). However, whether the parameters of NMM could track the effects of anesthesia still unknown.We proposed using the cortical NMM (CNMM) to infer the potential neurophysiological mechanism of three different anesthetic drugs (i.e. propofol, sevoflurane, and (S)-ketamine) induced GA, and we employed unscented Kalman filter (UKF) to track any change in raw electroencephalography (rEEG) in frontal area during GA. We did this by estimating the parameters of population gain [i.e. excitatory/inhibitory postsynaptic potential (EPSP/IPSP, i.e. parameter/in CNMM) and the time constant rate of EPSP/IPSP (i.e. parameter/in CNMM). We compared the rEEG and simulated EEG (sEEG) from the perspective of spectrum, phase-amplitude coupling (PAC), and permutation entropy (PE).. Under three estimated parameters (i.e., andfor propofol/sevoflurane orfor (S)-ketamine), the rEEG and sEEG had similar waveforms, time-frequency spectra, and PAC patterns during GA for the three drugs. The PE curves derived from rEEG and sEEG had high correlation coefficients (propofol: 0.97 ± 0.03, sevoflurane: 0.96 ± 0.03, (S)-ketamine: 0.98 ± 0.02) and coefficients of determination () (propofol: 0.86 ± 0.03, sevoflurane: 0.68 ± 0.30, (S)-ketamine: 0.70 ± 0.18). Except for parameterfor sevoflurane, the estimated parameters for each drug in CNMM can differentiate wakefulness and non-wakefulness states. Compared with the simulation of three estimated parameters, the UKF-based CNMM had lower tracking accuracy under the simulation of four estimated parameters (i.e.and) for three drugs.The results demonstrate that a combination of CNMM and UKF could track the neural activities during GA. The EPSP/IPSP and their time constant rate can interpret the anesthetic drug's effect on the brain, and can be used as a new index for depth of anesthesia monitoring.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/1741-2552/acc2e8 | DOI Listing |
Background: Lecanemab is a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils. In two clinical studies (phase 2, NCT01767311 and phase 3 ClarityAD, NCT03887455) in early Alzheimer's disease, lecanemab substantially reduced amyloid PET and significantly slowed clinical decline on multiple measures of cognition and function, including CDR-SB at 18 months. Models describing the change in amyloid PET and CDR-SB in response to lecanemab treatment were used to explore the impact of changing from the initial dosage regimen (10 mg/kg every 2 weeks [Q2W]) to a less intensive maintenance dosing regimen (10 mg/kg every 4 weeks [Q4W]) on clinical efficacy, and to explore the optimal duration of the initial dosing regimen.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) is the most prevalent cause of dementia accounting for an estimated 60% to 80% of cases. Despite advances in the research field, developing truly effective therapies for AD symptoms remains a major challenge. Sweet almond contain nutrients that have the potential of combating age-related brain dysfunction, by improving learning, memory and neurocognitive performance.
View Article and Find Full Text PDFBackground: The present study demonstrates the design, synthesis and pharmacological evaluation of coumarin-oxadiazole hybrids as potential molecules of therapeutic significance for the treatment of cognitive dysfunction.
Method: Eight novel coumarin-oxadiazole hybrids have been synthesized by employing suitable synthetic procedures and characterized by various spectral techniques i.e.
Alzheimers Dement
December 2024
University of California, Irvine, Irvine, CA, USA.
Background: Amid recent approvals, early Alzheimer's disease (AD) remains an active area of treatment development, but research on the utility of recruitment incentives in early AD trials remains limited. We examined how trial design features impact enrollment decisions among Mild Cognitive Impairment (MCI) patients and their family members.
Method: We performed a conjoint analysis experiment to compare early AD patients' preferences for trial features.
Alzheimers Dement
December 2024
The Pennsylvania State University, University Park, PA, USA.
Background: Loneliness is linked with risk for cognitive decline and dementia among older adults, but the degree to which it predicts future risk is unclear. To investigate if loneliness acts as a predictor of cognitive decline, this study employed a measurement burst design using data from the Einstein Aging Study, where loneliness and cognition were repeatedly assessed daily, for several days, across several years. In this type of data, a major challenge to detecting subtle cognitive changes is the presence of retest/practice effects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!